Szilard Kiss, MD
Show Description +
Szilárd Kiss, MD, explains the structure and 6-month results of the OPTIC trial, a phase 1 study that evaluated ADVM-022 (Adverum Biotechnologies), a novel intravitreal gene therapy for the treatment of wet age-related macular degeneration.
Posted: 10/21/2019
Szilard Kiss, MD
Szilárd Kiss, MD, explains the structure and 6-month results of the OPTIC trial, a phase 1 study that evaluated ADVM-022 (Adverum Biotechnologies), a novel intravitreal gene therapy for the treatment of wet age-related macular degeneration.
Posted: 10/21/2019
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2019.
Please log in to leave a comment.